The war on branded drugs: The Tipline for 30 July 2019

The waves of Actavis are still churning and they reached the shores of The Golden State yesterday. The state of California settled its pay-for-delay claims related to narcolepsy drug Provigil against Teva Pharmaceuticals. California attorney general Xavier Beccera said the resolution was the largest state-secured settlement related to reverse payments and the first to include injunctive relief barring similar agreements. Celgene, Mylan Laboratories and Sun Pharmaceuticals all settled claims they had illegally denied generic entry of branded medications on Friday. Speaking of Mylan, Pfizer announced plans to merge its generic drugs business with Mylan yesterday.

Get unlimited access to all Global Competition Review content